Comparison of animal models for head and neck cancer cachexia

Laryngoscope

Volumn 117, Issue 12, 2007, Pages 2152-2158

  Cannon, Trinitia ^a   Couch, Marion ^a   Yin, Xiaoying ^a   Guttridge, Denis ^b   Lai, Victor ^a   Shores, Carol ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer cachexia; JHU022; Lipid mobilizing factor; Murine adenocarcinoma 16 cell line; Muscle wasting

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CANCER CELL; CONTROLLED STUDY; FEMALE; FOOD INTAKE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LEAN BODY WEIGHT; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; BODY COMPOSITION; CACHEXIA; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 40349084155     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e3181453658     Document Type: Article

References (23)

1. Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 1999;8:133-136.
2. Buntzel J, Kuttner K. Value of megestrol acetate in treatment of cachexia in head-neck tumors. Laryngorhinootologie 1995;74:504-507.
3. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and neck cancer patients. Part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck 2007;29:401-411.
4. George J, Cannon T, Lai V, et al. Cancer cachexia syndrome in head and neck cancer patients: part II. Pathophysiology. Head Neck 2007;29:497-507.
5. Theologides A. Cancer cachexia. Cancer 1979;43(5 Suppl):2004-2012.
6. Lawson DH, Richmond A, Nixon DW, Rudman D. Metabolic approaches to cancer cachexia. Annu Rev Nutr 1982;2:277-301.
7. van Eys J. Nutrition and cancer: physiological interrelationships. Annu Rev Nutr 1985;5:435-461.
8. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497.
9. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998;58:2353-2358.
10. Bing C, Bao Y, Jenkins J, et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 2004;101:2500-2505.
11. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998;58:2359-2365.
12. Russell ST, Hirai K, Tisdale MJ. Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 2002;86:424-428.
13. Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 1987;205:368-376.
14. Groundwater P, Beck SA, Barton C, Adamson C, Ferrier IN, Tisdale MJ. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 1990;62:816-821.
15. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47:5919-5923.
16. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-563.
17. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-1227.
18. Sherry BA, Gelin J, Fong Y, et al. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. Faseb J 1989;3:1956-1962.
19. Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 1987;45:348-355.
20. Balkwill F, Osborne R, Burke F, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987;2:1229-1232.
21. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988;80:595-598.
22. Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol 1993;150:2341-2345.
23. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves JW, Lindsay R. Precision, accuracy, and reproducibility of dual x-ray absorptiometry measurements in mice in vivo. J Clin Densitom 2003;6:25-33.